GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:20000453 | Cervix | CC | regulation of G1/S transition of mitotic cell cycle | 37/2311 | 142/18723 | 6.33e-06 | 1.53e-04 | 37 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:19028062 | Cervix | CC | regulation of cell cycle G1/S phase transition | 41/2311 | 168/18723 | 1.18e-05 | 2.51e-04 | 41 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
GO:00102126 | Cervix | CC | response to ionizing radiation | 34/2311 | 148/18723 | 2.23e-04 | 2.53e-03 | 34 |
GO:00457862 | Cervix | CC | negative regulation of cell cycle | 67/2311 | 385/18723 | 2.21e-03 | 1.59e-02 | 67 |
GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
GO:00459302 | Cervix | CC | negative regulation of mitotic cell cycle | 44/2311 | 235/18723 | 3.02e-03 | 1.99e-02 | 44 |
GO:00427705 | Cervix | CC | signal transduction in response to DNA damage | 34/2311 | 172/18723 | 3.52e-03 | 2.27e-02 | 34 |
GO:19019912 | Cervix | CC | negative regulation of mitotic cell cycle phase transition | 35/2311 | 179/18723 | 3.73e-03 | 2.38e-02 | 35 |
GO:20001341 | Cervix | CC | negative regulation of G1/S transition of mitotic cell cycle | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
GO:00109482 | Cervix | CC | negative regulation of cell cycle process | 51/2311 | 294/18723 | 7.35e-03 | 3.94e-02 | 51 |
GO:00315715 | Cervix | CC | mitotic G1 DNA damage checkpoint | 9/2311 | 30/18723 | 8.28e-03 | 4.28e-02 | 9 |
GO:19028071 | Cervix | CC | negative regulation of cell cycle G1/S phase transition | 20/2311 | 93/18723 | 8.80e-03 | 4.50e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RFWD3 | SNV | Missense_Mutation | | c.2204N>T | p.Ser735Leu | p.S735L | Q6PCD5 | protein_coding | tolerated(0.06) | benign(0.01) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RFWD3 | SNV | Missense_Mutation | | c.1334N>G | p.Ser445Cys | p.S445C | Q6PCD5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RFWD3 | SNV | Missense_Mutation | | c.244N>C | p.Glu82Gln | p.E82Q | Q6PCD5 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.996) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RFWD3 | SNV | Missense_Mutation | | c.1219N>G | p.Gln407Glu | p.Q407E | Q6PCD5 | protein_coding | tolerated(0.48) | benign(0.021) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RFWD3 | SNV | Missense_Mutation | rs747018311 | c.1211N>T | p.Thr404Met | p.T404M | Q6PCD5 | protein_coding | tolerated(0.39) | benign(0) | TCGA-E2-A1B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Adriamycin | SD |
RFWD3 | insertion | Frame_Shift_Ins | novel | c.178_179insACAGACAGTGCCAGGTAAATAAATATATGGATAAGTCTGTGATCAT | p.Val60AspfsTer35 | p.V60Dfs*35 | Q6PCD5 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
RFWD3 | insertion | Frame_Shift_Ins | novel | c.1227_1228insTA | p.Asn410Ter | p.N410* | Q6PCD5 | protein_coding | | | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
RFWD3 | SNV | Missense_Mutation | novel | c.356N>T | p.Ser119Leu | p.S119L | Q6PCD5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
RFWD3 | SNV | Missense_Mutation | novel | c.2198G>A | p.Ser733Asn | p.S733N | Q6PCD5 | protein_coding | tolerated(0.07) | benign(0.037) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
RFWD3 | insertion | Nonsense_Mutation | novel | c.532_533insAAGCTTCA | p.Leu178Ter | p.L178* | Q6PCD5 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |